Over the past three decades, the New Technology and Gene Therapy (NTGT) Workshop has provided a valuable opportunity for leading researchers and clinicians to exchange knowledge, discuss emerging developments, and consider the future of care for people with hemophilia and other inherited bleeding disorders.
Initially hosted by the National Bleeding Disorders Foundation (NBDF), the workshop has evolved alongside some of the most significant advances in the field. Building on this legacy, the WFH assumed leadership of the workshop with the 18th edition in 2024. The 2026 meeting marks the second consecutive edition convened by the WFH and reflects the federation’s ongoing commitment to fostering collaboration and innovation across the global bleeding disorders community.
The treatment landscape today is dramatically different from what it was when the first workshop took place in 1996. At that time, treatment options for hemophilia were far more limited than they are today. A decade later, the first liver-directed gene therapy trial in hemophilia B had begun, and, by 2017, non-factor therapies were reshaping prophylactic care. Today, gene therapy is commercially available in some countries; this is just another step in the scientific journey that this workshop has followed.
The 2026 program will bring together experts in hematology, immunology, clinical research, biotechnology, and patient advocacy to examine the latest developments in new protein technologies, adeno-associated virus (AAV) gene therapies and other delivery systems, gene editing, and novel therapies for other bleeding disorders. The workshop will also feature a dedicated discussion on clinical trial participation and patient enrolment, exploring factors that influence enrolment decisions from both patient and investigator perspectives.
As the global research community continues to push the boundaries of treatment development, the 19th edition of the NTGT will serve as a forum for scientific discussion, knowledge exchange, and critical examination of the opportunities and challenges shaping the future of bleeding disorders care.
Through initiatives such as the New Technology and Gene Therapy (NTGT) Workshop , the WFH remains committed to supporting collaboration, advancing knowledge, and helping drive progress toward a future in which people with bleeding disorders everywhere can benefit from the latest scientific breakthroughs.
The 19th WFH New Technology and Gene Therapy Workshop is supported by:
- Visionary partners: Pfizer
- Collaborating partner: Regeneron, Roche, Sobi
- With additional thanks to: Metagenomi